Introduction: Plaque psoriasis, a chronic immune-mediated skin disorder, is characterized by well-demarcated erythematous plaques with silvery scales. This condition stems from complex interactions between genetic predisposition, immune dysregulation, and environmental triggers. Tapinarof downregulates the cytokine IL-17, diminishes the inflammatory infiltrate, and provides antioxidant properties while enhancing the expression of skin barrier proteins.
Areas Covered: This review begins by assessing tapinarof's mechanism in treating plaque psoriasis. Subsequently, it examines the effectiveness and safety of tapinarof 1% cream in adult patients.
Expert Opinion: Tapinarof 1% cream, which works by activating the aryl hydrocarbon receptor, is an FDA-approved treatment for adult plaque psoriasis. This therapy introduces a novel, nonsteroidal method for addressing inflammation and skin barrier issues, potentially serving as an alternative to conventional treatments. The once-daily, convenient cream formulation and favorable safety profile may enhance patient adherence, which is often poor with topical treatments. Tapinarof also maintains disease clearance for a mean of 4 months after treatment cessation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/1744666X.2023.2296607 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
IL-17 and IL-23 inhibitors have shown successful results in improving skin lesions in the treatment of moderate-to-severe plaque psoriasis. However, psoriasis is a chronic inflammatory disease characterized by systemic inflammation including joints in addition to skin lesions. Therefore, in this retrospective and observational cohort study, we aimed to evaluate the effect of IL-17 inhibitors (secukinumab and ixekizumab) and IL-23 inhibitors (risankizumab and guselkumab) on systemic inflammation in psoriasis.
View Article and Find Full Text PDFParadoxical infections and infestation in patients with chronic plaque psoriasis receiving interleukin 17A inhibitors - a tropical encounter with biologics.
Arch Dermatol Res
January 2025
Department of Dermatology, Head of research Centre, Father Muller Medical College, Mangalore, India.
Certolizumab pegol in severe hidradenitis suppurativa in pregnancy: A case report.
SAGE Open Med Case Rep
January 2025
Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy.
Hidradenitis suppurativa is a chronic inflammatory disease of the skin with a suppurative-cicatricial outcome affecting the infundibular component of the pilo-sebaceous unit. The lesions are typically localized in the intertriginous and apocrine gland-rich areas. Hidradenitis suppurativa mainly affects patients at a young age and is very often refractory to conventional medical treatment.
View Article and Find Full Text PDFReal-World Experience Using Bimekizumab in a Patient Cohort With Plaque-Type Psoriasis and Chronic Kidney Disease: A 48-Week Retrospective Multicentre Study.
Int J Dermatol
January 2025
Institute of Dermatology, Department of Medicine, University of Udine, Udine, Italy.
A Hybrid Model for Psoriasis Subtype Classification: Integrating Multi Transfer Learning and Hard Voting Ensemble Models.
Diagnostics (Basel)
December 2024
Department of Dermatology, Faculty of Medicine, Firat University, 23200 Elazig, Turkey.
Psoriasis is a chronic, immune-mediated skin disease characterized by lifelong persistence and fluctuating symptoms. The clinical similarities among its subtypes and the diversity of symptoms present challenges in diagnosis. Early diagnosis plays a vital role in preventing the spread of lesions and improving patients' quality of life.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!